FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
  1. Home
  2. GLENMARK Forum

GLENMARK

508.35 -3.65 (-0.71%)
Updated 03:29 24/09 IST
93% Bullish
7% Bearish
13 Users have submitted 14 trade ideas of Rs. 993,425 for GLENMARK
Disclaimer

Brokerage Reports

No. of reports in last year
8
No. of analysts
6
Average Consensus Forecast
543.5
Consensus Potential
4.46%
See GLENMARK Share Price Targets >>

GLENMARK Share Price Discussion


Type
Buy
Instrument
GLENMARK
Entry Price
₹507.8
Price@Trade
₹507.95
Target Price
₹550
Stop Price
₹475
Valid Till
Sep 23, 2022 3:20 AM
Margin
₹101,560 approx for 200 Qty
Status
Waiting for entry
Like
Reply
swap_vert
Trade

Type
Buy
Instrument
GLENMARK SEP21 510 CE
Entry Price
₹14.35
Price@Trade
₹14.35
Target Price
₹20.35
Stop Price
₹10
Valid Till
Sep 30, 2021 3:20 AM
Margin
₹16,502.5 approx for 1150 Qty
Status
Stoploss Hit
Exit Price
₹10
Net P&L
-₹5,002.5 (-30.31%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Sep 24 4:04 AM

Update
Stoploss Hit
Exit Price
₹10
S
Reputation: 0 • Sep 23 7:12 AM

Type
Buy
Instrument
GLENMARK
Entry Price
₹511
Price@Trade
₹511.8
Target Price
₹550
Stop Price
₹480
Valid Till
Oct 22, 2021 3:20 AM
Margin
₹25,550 approx for 50 Qty
Status
Active
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Sep 23 9:00 AM

Update
Trade Entered
Entry Price
₹511

Type
Buy
Instrument
GLENMARK
Entry Price
₹514.4
Price@Trade
₹514.4
Target Price
₹517  ₹527
Stop Price
₹510
Valid Till
Sep 24, 2021 3:20 AM
Margin
₹5,144 approx for 10 Qty
Status
Stoploss Hit
Exit Price
₹510
Net P&L
-₹44 (-0.86%)
Like
Reply (2)
swap_vert
Trade
See all replies
3NBusiness @3nbusiness
Sep 23 3:24 AM

Update
Target Extended
Price @ Update
₹514.5
Original Target
₹517
New Target
527.0
TrackerBot @trackerbot
Sep 23 5:01 AM

Update
Stoploss Hit
Exit Price
₹510
A
Reputation: 0 • Sep 23 2:49 AM

Type
Buy
Instrument
GLENMARK
Entry Price
₹514
Price@Trade
₹514.5
Target Price
₹519
Stop Price
₹510
Valid Till
Sep 23, 2021 3:20 AM
Margin
₹102,800 approx for 200 Qty
Status
Stoploss Hit
Exit Price
₹510
Net P&L
-₹800 (-0.78%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Sep 23 2:50 AM

Update
Trade Entered
Entry Price
₹514
TrackerBot @trackerbot
Sep 23 5:01 AM

Update
Stoploss Hit
Exit Price
₹510
Like
Reply

Type
Buy
Instrument
GLENMARK
Entry Price
₹513.35
Price@Trade
₹513.35
Target Price
₹550
Stop Price
₹300
Valid Till
Sep 22, 2022 3:20 AM
Margin
₹102,670 approx for 200 Qty
Status
Active
Like
Reply
swap_vert
Trade
Like
Reply
S
Reputation: 0 • Sep 22 4:28 AM

Type
Buy
Instrument
GLENMARK
Entry Price
₹494
Price@Trade
₹510.85
Target Price
₹519
Stop Price
₹489
Valid Till
Oct 22, 2021 3:20 AM
Margin
₹49,400 approx for 100 Qty
Status
Waiting for entry
Like
Reply
swap_vert
Trade
C
Reputation: 1,219 • Sep 22 3:50 AM

Type
Buy
Instrument
GLENMARK
Entry Price
₹512.8
Price@Trade
₹512.8
Target Price
₹530
Stop Price
₹506
Valid Till
Oct 22, 2021 3:20 AM
Margin
₹512,800 approx for 1000 Qty
Status
Active
Like
Reply
swap_vert
Trade
V
Reputation: 18,980 • Sep 21 7:13 AM
Like
Reply

Type
Buy
Instrument
GLENMARK
Entry Price
₹504.2
Price@Trade
₹504.2
Target Price
₹520
Stop Price
₹495
Valid Till
Oct 21, 2021 3:20 AM
Margin
₹50,420 approx for 100 Qty
Status
Active
Like
Reply
swap_vert
Trade

Type
Buy
Instrument
GLENMARK SEP21 500 CE
Entry Price
₹19
Price@Trade
₹19.75
Target Price
₹28
Stop Price
₹15  ₹18
Valid Till
Sep 30, 2021 3:20 AM
Margin
₹21,850 approx for 1150 Qty
Status
Exited
Exit Price
₹22.1
Net P&L
+₹3,565 (+16.32%)
Like
Reply (3)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Sep 21 6:39 AM

Update
Trade Entered
Entry Price
₹19
Vini @vini-Hy7LOp7ZF
Sep 21 8:17 AM

Update
Stoploss Trailed
Price @ Update
₹20
Original SL
₹15
New SL
18.0
Vini @vini-Hy7LOp7ZF
Sep 22 5:36 AM

Update
Exited
Exit Price
₹22.1
Net P&L
+₹3,565 (+16.32%)

Type
Sell
Instrument
GLENMARK
Entry Price
₹500
Price@Trade
₹500.7
Target Price
₹300
Stop Price
₹505
Valid Till
Oct 21, 2021 3:20 AM
Margin
₹500 approx for 1 Qty
Status
Waiting for entry
Like
Reply
swap_vert
Trade

Type
Buy
Instrument
GLENMARK SEP21 510 CE
Entry Price
₹13.7
Price@Trade
₹13.7
Target Price
₹20
Stop Price
₹11
Valid Till
Sep 30, 2021 3:20 AM
Margin
₹15,755 approx for 1150 Qty
Status
Exited
Exit Price
₹14.65
Net P&L
+₹1,092.5 (+6.93%)
Like
Reply (1)
swap_vert
Trade
See all replies
Monil Jain @moniljain
Sep 21 7:11 AM

Update
Exited
Exit Price
₹14.65
Net P&L
+₹1,092.5 (+6.93%)
Like
Reply (1)
See all replies
Billion Club @100billionclub
Sep 21 8:29 AM

ONCE EXIT SHORT IN GLENMARK SEP AT 508. BOOK LOSS RS. 10,350
N
Reputation: 0 • Sep 21 3:48 AM

Type
Sell
Instrument
GLENMARK
Entry Price
₹497
Price@Trade
₹497.4
Target Price
₹492
Stop Price
₹501
Valid Till
Sep 21, 2021 3:20 AM
Margin
₹24,850 approx for 50 Qty
Status
Stoploss Hit
Exit Price
₹501
Net P&L
-₹200 (-0.8%)
Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Sep 21 3:49 AM

Update
Trade Entered
Entry Price
₹497
TrackerBot @trackerbot
Sep 21 3:56 AM

Update
Stoploss Hit
Exit Price
₹501

Type
Buy
Instrument
GLENMARK SEP21 510 CE
Entry Price
₹19.2
Price@Trade
₹13.95
Target Price
₹30
Stop Price
₹15
Valid Till
Sep 21, 2021 3:20 AM
Margin
₹22,080 approx for 1150 Qty
Status
Exited before entry
Like
Reply (1)
swap_vert
Trade
See all replies

Update
Exited before entry
Price @ Update
₹12

Type
Buy
Instrument
GLENMARK
Entry Price
₹501.3
Price@Trade
₹501.3
Target Price
₹505
Stop Price
₹495
Valid Till
Sep 21, 2021 3:20 AM
Margin
₹7,519.5 approx for 15 Qty
Status
Target Achieved
Exit Price
₹505
Net P&L
+₹55.5 (+0.74%)
Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Sep 21 3:35 AM

Update
Target Achieved
Exit Price
₹505

Type
Buy
Instrument
GLENMARK OCT21 FUT
Entry Price
₹500
Price@Trade
₹500
Target Price
₹600
Stop Price
₹485
Valid Till
Oct 28, 2021 3:20 AM
Margin
₹228,574 approx for 1150 Qty
Status
Exited
Exit Price
₹515.5
Net P&L
+₹17,825 (+7.8%)
Like
Reply (1)
swap_vert
Trade
See all replies
Ummed Rajput @ummedrajput
Sep 23 7:44 AM

Update
Exited
Exit Price
₹515.5
Net P&L
+₹17,825 (+7.8%)

GLENMARK Ratings

Long term GLENMARK rating by FrontPage users
3.1/5 (7 Ratings)
Find answers to all your questions on live GLENMARK message board: Is GLENMARK buy or sell? Should I buy GLENMARK shares? Why are GLENMARK shares falling? Should I invest in GLENMARK stock?

Join FrontPage
Hero Img
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • GLENMARK - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization14,876.17
    Enterprise Value17,679.79
    Price to Earnings14.67
    Price to Book Value1.43
    Return on Capital Employed0.11
    Return on Equity0.1
    Face Value1
    Dividend YieldNA
  • GLENMARK - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    16-Aug-21Motilal OswalNeutral600
    1-Jun-21Prabhudas LilladherReduce509
    15-Feb-21ICICIdirect.comBuy635
    7-Dec-20EdelweissBuy559
    27-Nov-20Geojit Financial ServicesBuy548
    GLENMARK Brokerage Price Target
  • GLENMARK Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Sep 24512.5515.45500.3508.1
    Sep 23514516508.6512
    Sep 22507.9514.55507.35511.95
    Sep 21496508489.15506.2
    Sep 20518.85518.85492.2494.6
  • GLENMARK Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹523.18
    30 Day Moving Average₹529.87
    50 Day Moving Average₹566.58
    100 Day Moving Average₹596.6
    200 Day Moving Average₹549.39
  • GLENMARK - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue6,4037,989.23-0.2
    Operating Profit1,3472,662.19-0.49
    Profit Before Tax1,2192,552.9-0.52
    Net Income1,0142,140.61-0.53
  • GLENMARK - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Shareholder's Funds10,3919,436.620.1
    Total Liabilities5,2694,790.480.1
    Total Assets15,66114,227.10.1
  • GLENMARK - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity1,124877.720.28
    Cash from Investing Activity-1,137-2,580.46-0.56
    Cash from Financing Activity-621,879.38-1.03
    Net Cash Flow-75176.64-1.42
  • GLENMARK - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.060.15
    Return on Equity0.10.23
    Return on Capital Employed0.110.22
  • GLENMARK - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.23
    3 Year CAGR Growth in Operating Profit0.04
    3 Year CAGR Growth in EBIDTA0.11
    3 Year CAGR Growth in Net Income0.01
    3 Yr CAGR Growth - Diluted EPS-0.03
  • GLENMARK - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue2.16
    5 Year CAGR Growth in Operating Profit3.05
    5 Year CAGR Growth in EBIDTA2.4
    5 Year CAGR Growth in Net Income1.63
    3 Yr CAGR Growth - Diluted EPS1.52
  • GLENMARK - Recent News

    keyboard_arrow_down
    NewsBot
    Sep 21 2:31 AM
    Sell Glenmark Pharmaceuticals, target price Rs 470: ICICI Direct
    The Economic Times
    NewsBot
    Sep 15 7:51 AM
    Glenmark concludes study on COVID drug Favipiravir
    The Economic Times
    NewsBot
    Aug 6 3:26 AM
    Glenmark Life Sciences lists at 4% premium over issue price
    The Economic Times
    NewsBot
    Aug 5 4:21 AM
    Pharma has enough legs to boost stocks; in telecom, better to be on sidelines: Chakri Lokapriya
    The Economic Times
    NewsBot
    Aug 5 12:26 PM
    IPO Street’s paved with gold? Retail investors can’t stop buying
    The Economic Times
    NewsBot
    Aug 2 5:16 AM
    Glenmark inks deal with SaNOtize for COVID treatment spray in India, other Asian markets
    The Economic Times
    NewsBot
    Jul 30 2:01 AM
    Glenmark Life’s IPO subscribed over 45X
    The Economic Times
    NewsBot
    Jul 27 2:11 AM
    SGX Nifty up 45 points; here's what changed for market while you were sleeping
    The Economic Times
    NewsBot
    Jul 27 12:26 PM
    Glenmark Life IPO attractively priced
    The Economic Times
    NewsBot
    Jul 27 6:16 AM
    Glenmark Life Sciences mobilises Rs 454 cr from anchor investors ahead of IPO
    The Economic Times
  • GLENMARK - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Apollo Hospitals Enterprise Ltd. NSE:...
  • GLENMARK - More Information

    keyboard_arrow_down

    Glenmark Pharmaceuticals Ltd:
    Glenmark Pharmaceuticals, a company that deals with pharmaceutical products, was established in 1977 by Gracias Saldanha which headquarter is in Mumbai, India. It manufactures generic drugs and various active pharmaceutical ingredients.
    The company was named after the name of his two sons, Glenn and Mark. In the beginning, the company used to sell the products in India, Africa, and Russia. The company came to the public in the year 1999, and also took some procedures and built its research facility for the first time. Glenmark Saldanha’s elder son Glenn had the invasion as the CEO of the company in 2001 after working at PricewaterhouseCoopers when he came back to India.
    In 2008, Glenmark became the fifth-biggest company for pharmaceuticals in India. Glenmark entered into the market of dermatology by launching ‘Candid Cream’. Dermatology is one of the key focus areas of Glenmark, until today.
    About Company Information:
    The company entered the market of dermatology by launching Candid Cream in 1979, at the very beginning. In 1980, the company began to export their products outside of the country. In 1983, it incorporated its manufacturing facility for the very first time at Nasik, Maharashtra.
    The R&D department was founded in the plant at Nasik in 1984. The company introduced Ascoril in the market in 1987. The company initiated operating its business in Srilanka, Afghanistan, Mauritius, and Kenya in 1989. It expanded the plant at Nasik in 1992. It integrated a wholly possessed subordinate company, Glenmark Exports Pvt Ltd to strengthen its position internationally in the market of pharmaceuticals in 1996.
    In Brazil, the company started to sell pharmaceutical products in 1999. The company entered into the segment of diabetes in 2000. The company initiated the business of manufacturing API in 2001. It obtained a facility of API manufacturing from Glaxosmithkline Pharmaceuticals at Ankleshwar, Gujarat in 2002. Glenmark has done its out-licensing deal for the first time to discover R&D in 2004.
    The company commissioned a new facility for manufacture at Baddi, Himachal Pradesh in 2005. It signed an out-licensing contract with Merk KGaA, Germany in 2006, for Melogliptin. The company received the approval of MHRA, the UK for their plant at Baddi in 2007.
    The company re-organized its business and integrated a company namely Glenmark Generics as its subordinate one in 2008. During 2009-10, it integrated Glenmark Generics B.V. in the Netherlands. Glenmark signed the Development Agreement with Forest Laboratories to collaborate on Novel Agents.
    The company made the announcement of launching a cream namely Hydrocortisone Butyrate in the US, in 2013. Glenmark brought together its two subsidiary companies which are Glenmark Generics Ltd. and Glenmark Access Ltd. with GPL in the year 2014. The company disclosed its approval and launching of Verapamil and Trandolapril Hydrochloride in 2015.
    Glenmark announced the strategic blueprint of its evolution to an innovation-led globally spread pharmaceutical organization on 19th December 2016. The blueprint bears its greater alignment of business spreading generics to give priority mostly to the research and development efforts in three core therapeutic sections: respiratory, oncology and dermatology.
    The company announced affirmative results for GSP 301 on 30th March 2017. The company has also announced that it has submitted an NDA to the FDA of US for Ryaltris, the respiratory pipeline candidate, which is basically a tentative fixed-dose nasal spray which is a combination of a steroid and an antihistamine that is used for treatment of seasonal allergic rhinitis (SAR) and it was announced on 22nd May 2018.
    The company announced on 19th June 2018 that the first supplemental Abbreviated New Drug Application (SANDA) was provided by the US Food and Drug Administration for the manufacturing facility of the company in Monroe, New Carolina. The Monroe facility in New Carolina is the first manufacturing plant of Glenmark in the US which is founded to manufacture various pharmaceutical products of fixed does. The company has made an investment of more than $100 million on that facility along with some planning of further development in upcoming years.
    How Glenmark Pharmaceuticals Ltd is categorised as Pharmaceuticals and Health Care Sector and Pharmaceuticals Industry.
    Pharmaceuticals and Health care sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more. The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Glenmark Pharmaceuticals Ltd is categorized under the Pharmaceutical and Health care sector and Pharmaceutical Industry. The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Glenmark Pharmaceuticals Ltd, Competitors and Sector Peers:
    Abbott India Ltd. ABBIND
    Alembic Ltd. ALELTD
    Alembic Pharmaceuticals Ltd. ALEPHA
    Alkem Laboratories Ltd. ALKLAB
    Alpa Laboratories Ltd. ALPLAB
    Ambalal Sarabhai Enterprises Ltd. AMBSAR
    AstraZeneca Pharma India Ltd. ASTZEN
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Biocon Ltd. BIOLTD
    Cian Healthcare Ltd.
    Cipla Ltd. CIPLTD
    Concord Drugs Ltd. CONDRU
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    Lincoln Pharmaceuticals Ltd. LINPHA
    Lupin Ltd. LUPLTD
    Madhuveer Com 18 Network Ltd. TOHPHA
    Mahavir Advanced Remedies Ltd. INDAME
    Makers Laboratories Ltd. MAKLAB
    Natco Pharma Ltd. NATPHA
    Natural Capsules Ltd. NATCAP
    Ranbaxy Laboratories Ltd. RANLAB
    Sanofi India Ltd. AVEPHA
    Sharon Bio-Medicine Ltd. SHAPHA
    Sun Pharmaceutical Industries Ltd. SUN28
    Zenith Healthcare Ltd. ZENHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.